The 8 analysts offering 12-month price forecasts for Aeglea Bio Therapeutics Inc have a median target of 13.50, with a high estimate of 22.00 and a low estimate of 5.00. The median estimate represents a +221.43% increase from the last price of 4.20.
The current consensus among 8 polled investment analysts is to Buy stock in Aeglea Bio Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.29
Reporting Date Mar 16
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.